-
Innovation Ranking
NewInnovation Ranking – Viva Biotech Holdings
Viva Biotech Holdings (Viva Biotech) is a contract research biotech company that offers preclinical drug discovery services. The company provides services such as gene-to-protein and gene-to-structure, viva engine for lead discovery, membrane protein targeted discovery technology, medicinal chemistry, in vitro pharmacology and antibody discovery services. It offers cell lines, crystal structures, GPCR proteins and protein products. The company offers mouse monoclonal antibody generation with an advanced hybridoma platform, protein engineering, epitope mapping, antibody humanization and affinity maturation. It serves to...
-
Product Insights
Vis Viva Wind Farm
Vis Viva Wind Farm is an onshore wind project located in Buzau, Romania. The project is owned by Low Carbon Investment Management Ltd; Rezolv Energy Sro and is developed by NERO Renewables Romania SRL; Rezolv Energy Sro. The project is at the permitting stage. Empower your strategies with our Vis Viva Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to...
-
Sector Analysis
Bolivia Telecom Operators Country Intelligence Report
Bolivia Telecom Operators Country Intelligence Overview The total telecom and pay-TV service revenue in Bolivia reached $2.1 billion in 2023. The market size growth has been estimated to increase at a CAGR of more than 3% during 2023-2028, primarily supported by growth in fixed broadband and mobile data revenues. This growth is also supported by National Broadband Initiatives aimed at expanding and upgrading the country’s mobile and fiber network infrastructure as a part of the Fiber Optics Communications Installation Project...
-
Company Insights
Innovation and Patenting activity of Viva Biotech Holdings Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Viva Biotech Holdings Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target GD2 For Neuroblastoma in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target GD2 For Neuroblastoma in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target GD2 For Neuroblastoma...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Triple-Negative Breast Cancer (TNBC) Drug Details: Cabozantinib s-malate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VVN-461 in Ocular Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VVN-461 in Ocular Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VVN-461 in Ocular Inflammation Drug Details: VVN-461 is under development for...
-
Product Insights
Anterior Uveitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Anterior Uveitis - Drugs In Development, 2023’, provides an overview of the Anterior Uveitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ocular Hypertension – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Hypertension - Drugs In Development, 2023’, provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Open-Angle Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Open-Angle Glaucoma - Drugs In Development, 2023’, provides an overview of the Open-Angle Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...